Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide

Background: Heart rate variability represents a reliable marker to delineate the status of autonomic nervous system (ANS) function and alterations due to stress in vivo. Interestingly, up to now the effects of corticotropin-releasing hormone (CRH), a key regulator of the stress hormone system, upon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropeptides (Edinburgh) 2003-12, Vol.37 (6), p.362-368
Hauptverfasser: Arlt, Josef, Jahn, Holger, Kellner, Michael, Ströhle, Andreas, Yassouridis, Alexander, Wiedemann, Klaus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 368
container_issue 6
container_start_page 362
container_title Neuropeptides (Edinburgh)
container_volume 37
creator Arlt, Josef
Jahn, Holger
Kellner, Michael
Ströhle, Andreas
Yassouridis, Alexander
Wiedemann, Klaus
description Background: Heart rate variability represents a reliable marker to delineate the status of autonomic nervous system (ANS) function and alterations due to stress in vivo. Interestingly, up to now the effects of corticotropin-releasing hormone (CRH), a key regulator of the stress hormone system, upon heart rate variability are not sufficiently described. Hence, we attempted to investigate the ANS-effects of a CRH bolus and the modulatory influences of atrial natriuretic peptide (ANP), one of the most important functional antagonist of CRH actions. Methods: 12 healthy male volunteers were administered 100 μg CRH as bolus injection at 15:00. Six randomly chosen subjects received 150 μg ANP dissolved in normal saline and six subjects a normal saline infusion from 14:45 to 15:15. From 13:00 to 17:00 an ECG was recorded and mean heart rate (HR), total power (TP), very low frequency (VLF), low frequency (LF), LF in normalized units (LF [nu]), high frequency (HF) domains and the LF/HF-ratio in the interval from 14:00 to 16:00 were determined. Results: After administration of CRH a significant increase in HR and a fast reduction of TP were observed, which lasted about 1 h. Based upon spectral domain analyses the sympathetic activity after CRH administration as indicated by LF [nu] increased by 31% (mean location) during saline. Applying ANP this increase was reduced to 19% (mean location). The VLF component, which is considered to be based in part also on sympathetic influences, indicates comparable effect. During saline the VLF after CRH bolus remained largely unchanged, but was reduced to 66% by ANP. Though the vagal activity indicated by the HF component was reduced after CRH, no significant differences emerged between both treatments. The changes of the LF/HF-ratio were pronounced in both groups. During saline this ratio increased by about 111%, during ANP only by 43% (mean location). Conclusions: Based upon HRV analysis the CRH administration induced sympathotonic effects which were antagonized by ANP. The observed vagal changes were less pronounced and need further investigation. Further studies of autonomic effects by alterations of CRH secretion in depression and anxiety disorder are strongly warranted.
doi_str_mv 10.1016/j.npep.2003.09.006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71492421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0143417903000933</els_id><sourcerecordid>71492421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-77b73e4582a274d13521f5877429e42f41c27406ed0fed91cc84f5757cebeaf33</originalsourceid><addsrcrecordid>eNp9kE1r3DAURUVpaCZp_0AXRZtmZ0eSZUuGbErIRyGlm2YtNNJTosGWHEkOzL-PnRnIrqsLj_Mul4PQd0pqSmh3uavDBFPNCGlq0teEdJ_QhrYNq5iQ7We0IZQ3FaeiP0VnOe8IIZxJ-QWdUt71shP9Btk_0c6DLj4GHB3O-3HS5RmKN1ib4l992ePtHpuYllMsKU4-VAkG0NmHJ_wc0xgDYB0s1iV5PeCw5pzeK5Z5xVv4ik6cHjJ8O-Y5ery9-Xd9Xz38vft9_euhMpzLUgmxFQ3wVjLNBLe0aRl1rRSCsx44c5ya5U46sMSB7akxkrtWtMLAFrRrmnN0ceidUnyZIRc1-mxgGHSAOGclKO8ZZ3QB2QE0KeacwKkp-VGnvaJErW7VTq1u1epWkV4tbpenH8f2eTuC_Xg5ylyAn0dAZ6MHl3QwPn9wLe8k6daiqwMHi4tXD0ll4yEYsD6BKcpG_78db9RGmd8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71492421</pqid></control><display><type>article</type><title>Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Arlt, Josef ; Jahn, Holger ; Kellner, Michael ; Ströhle, Andreas ; Yassouridis, Alexander ; Wiedemann, Klaus</creator><creatorcontrib>Arlt, Josef ; Jahn, Holger ; Kellner, Michael ; Ströhle, Andreas ; Yassouridis, Alexander ; Wiedemann, Klaus</creatorcontrib><description>Background: Heart rate variability represents a reliable marker to delineate the status of autonomic nervous system (ANS) function and alterations due to stress in vivo. Interestingly, up to now the effects of corticotropin-releasing hormone (CRH), a key regulator of the stress hormone system, upon heart rate variability are not sufficiently described. Hence, we attempted to investigate the ANS-effects of a CRH bolus and the modulatory influences of atrial natriuretic peptide (ANP), one of the most important functional antagonist of CRH actions. Methods: 12 healthy male volunteers were administered 100 μg CRH as bolus injection at 15:00. Six randomly chosen subjects received 150 μg ANP dissolved in normal saline and six subjects a normal saline infusion from 14:45 to 15:15. From 13:00 to 17:00 an ECG was recorded and mean heart rate (HR), total power (TP), very low frequency (VLF), low frequency (LF), LF in normalized units (LF [nu]), high frequency (HF) domains and the LF/HF-ratio in the interval from 14:00 to 16:00 were determined. Results: After administration of CRH a significant increase in HR and a fast reduction of TP were observed, which lasted about 1 h. Based upon spectral domain analyses the sympathetic activity after CRH administration as indicated by LF [nu] increased by 31% (mean location) during saline. Applying ANP this increase was reduced to 19% (mean location). The VLF component, which is considered to be based in part also on sympathetic influences, indicates comparable effect. During saline the VLF after CRH bolus remained largely unchanged, but was reduced to 66% by ANP. Though the vagal activity indicated by the HF component was reduced after CRH, no significant differences emerged between both treatments. The changes of the LF/HF-ratio were pronounced in both groups. During saline this ratio increased by about 111%, during ANP only by 43% (mean location). Conclusions: Based upon HRV analysis the CRH administration induced sympathotonic effects which were antagonized by ANP. The observed vagal changes were less pronounced and need further investigation. Further studies of autonomic effects by alterations of CRH secretion in depression and anxiety disorder are strongly warranted.</description><identifier>ISSN: 0143-4179</identifier><identifier>EISSN: 1532-2785</identifier><identifier>DOI: 10.1016/j.npep.2003.09.006</identifier><identifier>PMID: 14698679</identifier><identifier>CODEN: NRPPDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Atrial Natriuretic Factor - administration &amp; dosage ; Atrial Natriuretic Factor - physiology ; Atrial natriuretic peptide ; Autonomic Nervous System - drug effects ; Autonomous nervous system ; Biological and medical sciences ; Blood Pressure - drug effects ; Corticotropin-releasing hormone ; Corticotropin-Releasing Hormone - administration &amp; dosage ; Corticotropin-Releasing Hormone - antagonists &amp; inhibitors ; Corticotropin-Releasing Hormone - physiology ; Electrocardiography ; Fundamental and applied biological sciences. Psychology ; Heart Rate - drug effects ; Heart rate variability ; Humans ; Hypothalamic–pituitary–adrenocortical system ; LF/HF-ratio ; Male ; Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ ; Reference Values ; Sympathetic Nervous System - drug effects ; Total power ; Vertebrates: endocrinology ; Vertebrates: nervous system and sense organs</subject><ispartof>Neuropeptides (Edinburgh), 2003-12, Vol.37 (6), p.362-368</ispartof><rights>2003 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-77b73e4582a274d13521f5877429e42f41c27406ed0fed91cc84f5757cebeaf33</citedby><cites>FETCH-LOGICAL-c448t-77b73e4582a274d13521f5877429e42f41c27406ed0fed91cc84f5757cebeaf33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0143417903000933$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15468066$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14698679$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arlt, Josef</creatorcontrib><creatorcontrib>Jahn, Holger</creatorcontrib><creatorcontrib>Kellner, Michael</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><creatorcontrib>Yassouridis, Alexander</creatorcontrib><creatorcontrib>Wiedemann, Klaus</creatorcontrib><title>Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide</title><title>Neuropeptides (Edinburgh)</title><addtitle>Neuropeptides</addtitle><description>Background: Heart rate variability represents a reliable marker to delineate the status of autonomic nervous system (ANS) function and alterations due to stress in vivo. Interestingly, up to now the effects of corticotropin-releasing hormone (CRH), a key regulator of the stress hormone system, upon heart rate variability are not sufficiently described. Hence, we attempted to investigate the ANS-effects of a CRH bolus and the modulatory influences of atrial natriuretic peptide (ANP), one of the most important functional antagonist of CRH actions. Methods: 12 healthy male volunteers were administered 100 μg CRH as bolus injection at 15:00. Six randomly chosen subjects received 150 μg ANP dissolved in normal saline and six subjects a normal saline infusion from 14:45 to 15:15. From 13:00 to 17:00 an ECG was recorded and mean heart rate (HR), total power (TP), very low frequency (VLF), low frequency (LF), LF in normalized units (LF [nu]), high frequency (HF) domains and the LF/HF-ratio in the interval from 14:00 to 16:00 were determined. Results: After administration of CRH a significant increase in HR and a fast reduction of TP were observed, which lasted about 1 h. Based upon spectral domain analyses the sympathetic activity after CRH administration as indicated by LF [nu] increased by 31% (mean location) during saline. Applying ANP this increase was reduced to 19% (mean location). The VLF component, which is considered to be based in part also on sympathetic influences, indicates comparable effect. During saline the VLF after CRH bolus remained largely unchanged, but was reduced to 66% by ANP. Though the vagal activity indicated by the HF component was reduced after CRH, no significant differences emerged between both treatments. The changes of the LF/HF-ratio were pronounced in both groups. During saline this ratio increased by about 111%, during ANP only by 43% (mean location). Conclusions: Based upon HRV analysis the CRH administration induced sympathotonic effects which were antagonized by ANP. The observed vagal changes were less pronounced and need further investigation. Further studies of autonomic effects by alterations of CRH secretion in depression and anxiety disorder are strongly warranted.</description><subject>Adult</subject><subject>Atrial Natriuretic Factor - administration &amp; dosage</subject><subject>Atrial Natriuretic Factor - physiology</subject><subject>Atrial natriuretic peptide</subject><subject>Autonomic Nervous System - drug effects</subject><subject>Autonomous nervous system</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Corticotropin-releasing hormone</subject><subject>Corticotropin-Releasing Hormone - administration &amp; dosage</subject><subject>Corticotropin-Releasing Hormone - antagonists &amp; inhibitors</subject><subject>Corticotropin-Releasing Hormone - physiology</subject><subject>Electrocardiography</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart Rate - drug effects</subject><subject>Heart rate variability</subject><subject>Humans</subject><subject>Hypothalamic–pituitary–adrenocortical system</subject><subject>LF/HF-ratio</subject><subject>Male</subject><subject>Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ</subject><subject>Reference Values</subject><subject>Sympathetic Nervous System - drug effects</subject><subject>Total power</subject><subject>Vertebrates: endocrinology</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0143-4179</issn><issn>1532-2785</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAURUVpaCZp_0AXRZtmZ0eSZUuGbErIRyGlm2YtNNJTosGWHEkOzL-PnRnIrqsLj_Mul4PQd0pqSmh3uavDBFPNCGlq0teEdJ_QhrYNq5iQ7We0IZQ3FaeiP0VnOe8IIZxJ-QWdUt71shP9Btk_0c6DLj4GHB3O-3HS5RmKN1ib4l992ePtHpuYllMsKU4-VAkG0NmHJ_wc0xgDYB0s1iV5PeCw5pzeK5Z5xVv4ik6cHjJ8O-Y5ery9-Xd9Xz38vft9_euhMpzLUgmxFQ3wVjLNBLe0aRl1rRSCsx44c5ya5U46sMSB7akxkrtWtMLAFrRrmnN0ceidUnyZIRc1-mxgGHSAOGclKO8ZZ3QB2QE0KeacwKkp-VGnvaJErW7VTq1u1epWkV4tbpenH8f2eTuC_Xg5ylyAn0dAZ6MHl3QwPn9wLe8k6daiqwMHi4tXD0ll4yEYsD6BKcpG_78db9RGmd8</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>Arlt, Josef</creator><creator>Jahn, Holger</creator><creator>Kellner, Michael</creator><creator>Ströhle, Andreas</creator><creator>Yassouridis, Alexander</creator><creator>Wiedemann, Klaus</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031201</creationdate><title>Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide</title><author>Arlt, Josef ; Jahn, Holger ; Kellner, Michael ; Ströhle, Andreas ; Yassouridis, Alexander ; Wiedemann, Klaus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-77b73e4582a274d13521f5877429e42f41c27406ed0fed91cc84f5757cebeaf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Atrial Natriuretic Factor - administration &amp; dosage</topic><topic>Atrial Natriuretic Factor - physiology</topic><topic>Atrial natriuretic peptide</topic><topic>Autonomic Nervous System - drug effects</topic><topic>Autonomous nervous system</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Corticotropin-releasing hormone</topic><topic>Corticotropin-Releasing Hormone - administration &amp; dosage</topic><topic>Corticotropin-Releasing Hormone - antagonists &amp; inhibitors</topic><topic>Corticotropin-Releasing Hormone - physiology</topic><topic>Electrocardiography</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart Rate - drug effects</topic><topic>Heart rate variability</topic><topic>Humans</topic><topic>Hypothalamic–pituitary–adrenocortical system</topic><topic>LF/HF-ratio</topic><topic>Male</topic><topic>Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ</topic><topic>Reference Values</topic><topic>Sympathetic Nervous System - drug effects</topic><topic>Total power</topic><topic>Vertebrates: endocrinology</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arlt, Josef</creatorcontrib><creatorcontrib>Jahn, Holger</creatorcontrib><creatorcontrib>Kellner, Michael</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><creatorcontrib>Yassouridis, Alexander</creatorcontrib><creatorcontrib>Wiedemann, Klaus</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropeptides (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arlt, Josef</au><au>Jahn, Holger</au><au>Kellner, Michael</au><au>Ströhle, Andreas</au><au>Yassouridis, Alexander</au><au>Wiedemann, Klaus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide</atitle><jtitle>Neuropeptides (Edinburgh)</jtitle><addtitle>Neuropeptides</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>37</volume><issue>6</issue><spage>362</spage><epage>368</epage><pages>362-368</pages><issn>0143-4179</issn><eissn>1532-2785</eissn><coden>NRPPDD</coden><abstract>Background: Heart rate variability represents a reliable marker to delineate the status of autonomic nervous system (ANS) function and alterations due to stress in vivo. Interestingly, up to now the effects of corticotropin-releasing hormone (CRH), a key regulator of the stress hormone system, upon heart rate variability are not sufficiently described. Hence, we attempted to investigate the ANS-effects of a CRH bolus and the modulatory influences of atrial natriuretic peptide (ANP), one of the most important functional antagonist of CRH actions. Methods: 12 healthy male volunteers were administered 100 μg CRH as bolus injection at 15:00. Six randomly chosen subjects received 150 μg ANP dissolved in normal saline and six subjects a normal saline infusion from 14:45 to 15:15. From 13:00 to 17:00 an ECG was recorded and mean heart rate (HR), total power (TP), very low frequency (VLF), low frequency (LF), LF in normalized units (LF [nu]), high frequency (HF) domains and the LF/HF-ratio in the interval from 14:00 to 16:00 were determined. Results: After administration of CRH a significant increase in HR and a fast reduction of TP were observed, which lasted about 1 h. Based upon spectral domain analyses the sympathetic activity after CRH administration as indicated by LF [nu] increased by 31% (mean location) during saline. Applying ANP this increase was reduced to 19% (mean location). The VLF component, which is considered to be based in part also on sympathetic influences, indicates comparable effect. During saline the VLF after CRH bolus remained largely unchanged, but was reduced to 66% by ANP. Though the vagal activity indicated by the HF component was reduced after CRH, no significant differences emerged between both treatments. The changes of the LF/HF-ratio were pronounced in both groups. During saline this ratio increased by about 111%, during ANP only by 43% (mean location). Conclusions: Based upon HRV analysis the CRH administration induced sympathotonic effects which were antagonized by ANP. The observed vagal changes were less pronounced and need further investigation. Further studies of autonomic effects by alterations of CRH secretion in depression and anxiety disorder are strongly warranted.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14698679</pmid><doi>10.1016/j.npep.2003.09.006</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0143-4179
ispartof Neuropeptides (Edinburgh), 2003-12, Vol.37 (6), p.362-368
issn 0143-4179
1532-2785
language eng
recordid cdi_proquest_miscellaneous_71492421
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adult
Atrial Natriuretic Factor - administration & dosage
Atrial Natriuretic Factor - physiology
Atrial natriuretic peptide
Autonomic Nervous System - drug effects
Autonomous nervous system
Biological and medical sciences
Blood Pressure - drug effects
Corticotropin-releasing hormone
Corticotropin-Releasing Hormone - administration & dosage
Corticotropin-Releasing Hormone - antagonists & inhibitors
Corticotropin-Releasing Hormone - physiology
Electrocardiography
Fundamental and applied biological sciences. Psychology
Heart Rate - drug effects
Heart rate variability
Humans
Hypothalamic–pituitary–adrenocortical system
LF/HF-ratio
Male
Peripheral nervous system. Autonomic nervous system. Neuromuscular transmission. Ganglionic transmission. Electric organ
Reference Values
Sympathetic Nervous System - drug effects
Total power
Vertebrates: endocrinology
Vertebrates: nervous system and sense organs
title Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A10%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modulation%20of%20sympathetic%20activity%20by%20corticotropin-releasing%20hormone%20and%20atrial%20natriuretic%20peptide&rft.jtitle=Neuropeptides%20(Edinburgh)&rft.au=Arlt,%20Josef&rft.date=2003-12-01&rft.volume=37&rft.issue=6&rft.spage=362&rft.epage=368&rft.pages=362-368&rft.issn=0143-4179&rft.eissn=1532-2785&rft.coden=NRPPDD&rft_id=info:doi/10.1016/j.npep.2003.09.006&rft_dat=%3Cproquest_cross%3E71492421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71492421&rft_id=info:pmid/14698679&rft_els_id=S0143417903000933&rfr_iscdi=true